Alluvi, formerly BI 4744, presents a promising breakthrough in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling efficacy in patient https://bookmark-group.com/story7934217/alluvi-a-comprehensive-investigation-into-retatrutide-s-prospects